Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1–120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice

A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease

(2010) Karl Kieburtz   ARCHIVES OF NEUROLOGY

SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease

(2010) Pablo Garcia-Reitböck et al.   BRAIN

Discovery of a Proneurogenic, Neuroprotective Chemical

(2010) Andrew A. Pieper et al.   CELL

Cognition-Enhancing Properties of Dimebon in a Rat Novel Object Recognition Task Are Unlikely to Be Associated with Acetylcholinesterase Inhibition or N-Methyl-D-aspartate Receptor Antagonism

(2010) M. Giorgetti et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models

(2009) Makiko Yamashita et al.   FEBS LETTERS

γ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein

(2009) Natalia Ninkina et al.   HUMAN MOLECULAR GENETICS

Liquid chromatography–tandem mass spectrometry method for the quantification of dimebon in rat plasma and brain tissue

(2009) Ramakrishna Nirogi et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo

(2009) John W Steele et al.   Molecular Neurodegeneration

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

(2008) Rachelle S Doody et al.   LANCET

Evaluation of Dimebon in cellular model of Huntington's disease

(2008) Jun Wu et al.   Molecular Neurodegeneration

Absence of α-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice

(2008) Abdelmojib Al-Wandi et al.   NEUROBIOLOGY OF AGING